CADILAHC Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > cadilahc

Technical Analysis

Technical Strength: 5.3 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 50.9. According to RSI analysis, cadilahc is marginally weak. 4.0 CADILAHC RSI Chart
MACD (?) MACD: 2.29 and Signal Line: 1.55. According to MACD analysis, cadilahc is technically strong. 8.0 CADILAHC MACD Chart
Simple Moving Average (?) 20-day simple moving average just got above it's 50-day simple moving average which is a positive signal. According to simple moving average analysis, cadilahc is facing resistance from it's 200-day simple moving average at 478.3127 and support level is at 436. 8.0 CADILAHC Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, cadilahc is facing resistance at 442 and support level is at 436.7828. 6.0 CADILAHC Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.564. 5.0 CADILAHC Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is below all levels. Resistance levels are 443.2599 and 456.175. Support level is 401.45. 2.5 CADILAHC Fibonacci Retracement Chart
Average True Range (?) ATR: 11 NA CADILAHC Average True Range Chart
Average Directional Index (?) ADX is 22.2 which means CADILAHC is in a trading range and there is no trend. NA CADILAHC Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
January 18, 2018
Open Price 441.95
High Price 446.0
Low Price 432.7
Close Price 437.6
Absolute Change -2.65
Percentage Change -0.602%
Weekly Change -1.64%
Monthly Change 4.34%
Yearly Change 25.1%
52-week high 560.0
52-week low 329.4
Corporate Actions
ExDate Purpose
July 27, 2017 ANNUAL GENERAL MEETING
March 16, 2017 INT DIV RS 3.20 PER SHARE
March 16, 2017 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.388
Confidence in Beta1.27%
Market Capital Rs. 8959.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 17.636
TTM Price-to-Earnings (P/E) Ratio 24.8
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 18 January 2018: Deliverable Quantity:1.26e+05 NA CADILAHC Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 18 January 2018: Daily Volatility:0.2426 NA CADILAHC Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 18 January 2018: PCR_OI:0.246 PCR:0.226 NA CADILAHC PCR Chart
Option Pain (?) 18 January 2018: Max Pain:440.0 NA CADILAHC Option Pain Chart
Premium (?) 18 January 2018 Premium: -0.15 Futures OI:5337600.0 NA CADILAHC Premium Chart
Option_MAX_OI (?) 18 January 2018: Price:437.6 Put with maximum OI:420.0 Call with maximum OI:460.0 NA CADILAHC Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
January 25, 2018 437.45 5337600.0 703.0 738.0 437.6
February 22, 2018 439.25 294400.0 139.0 147.0 437.6

Announcements

January 01, 2018 CaPress Releaseadila Healthcare Limited has informed the Exchange regarding a press release dated December 30, 2017, titled "Zydus receives final approval from the USFDA for Valacyclovir Tablets USP".
December 29, 2017 CaPress Releaseadila Healthcare Limited has informed the Exchange regarding a press release dated December 29, 2017, titled "Zydus receives final approval from the USFDA for Clomipramine Hydrochloride Capsules USP.".
See all Announcements

Board Meetings

Date Meeting Date Purpose
January 10, 2018 February 08, 2018 ToResults/Otherso consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2017.
October 11, 2017 November 14, 2017 TResultsTo consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017.
See all Board Meetings

CADILAHC is part of...

Index Weightage
CNXPHARMA NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 418.2 Rs. 425.5 Rs. 431.5 Rs. 438.8 Rs. 444.8 Rs. 452.1 Rs. 458.1